QIAGEN N.V.

Financial Report

2022

QIAGEN N.V.

Financial Report

2022

Overview

Management Report

Corporate Governance Report

Environmental, Social

and Governance

Financial Results

Consolidated Financial Statements

Notes to the Consolidated Financial Statements

List of Subsidiaries

Auditor's Report

Appendix

Content

About QIAGEN

4 Introduction

Overview

  1. Supervisory Board Report
  1. Executive Committee
  1. Common Shares

Management Report

  1. Business and Operating Environment
  1. Risks Management

95 Critical Accounting Policies, Judgments and Estimates

  1. Performance Review
  1. Human Capital
  1. Outlook

Corporate Governance Report

  1. Corporate Structure
  2. Managing Board
  3. Supervisory Board

124 Diversity within the Management Board and Supervisory Board

124 Compensation of Managing Board Members and Supervisory Directors

129 Additional Information

QIAGEN FINANC IAL REPORT 2022

3

Environmental, Social and Governance

  1. Our Approach to Sustainability
  1. Environmental Responsibility
  1. Invest in People
  1. Serving Societies
  1. Business with Integrity
  1. EU Taxonomy
  1. ESG performance at a glance

Financial Results

182 Consolidated Financial Statements

189 Notes to the Consolidated Financial Statements

  1. List of Subsidiaries
  1. Auditor's Report

Appendix

  1. Services
  2. Imprint

This document contains detailed financial information about QIAGEN prepared under generally accepted accounting standards in the U.S. (U.S. GAAP) and included in our Form 20-F annual report filed with the U.S. Securities and Exchange Commission. QIAGEN also publishes an Annual Report under IFRS accounting standards, which is available on our website at www.QIAGEN.com.

We help ­advance science and improve outcomes

Our Mission

Enabling access to valuable insights from molecular research­ to clinical healthcare

Our Vision

Making improvements in life possible

QIAGEN at a glance

Our products support scientists and ­clinicians to advance scientific­ ­discovery­ and improve patient outcomes

A global company with scaleSales

$2.1 L I S T E D

~45%

~20%

QGEN

billion

EMEA

NYSE

Americas

(2022 sales)

~35%

Asia-Pacific / Japan

Highly recurring revenues

Balanced customer markets

~88 %

~12 %

~50%

~50%

Consumables

and related

Molecular

Life

revenues

Instruments

Diagnostics

Sciences

~ 6,200

employees known as QIAGENers

> 500,000

customers worldwide

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Qiagen NV published this content on 10 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 May 2023 07:56:07 UTC.